Xiufan Liu

Title: Xiufan Liu: Innovator in Avian Influenza Vaccine Development

Introduction

Xiufan Liu is a prominent inventor based in Yangzhou, China. He has made significant contributions to the field of virology, particularly in the development of vaccines for avian influenza. His innovative work has implications for both animal health and public safety.

Latest Patents

Xiufan Liu holds a patent for a recombinant H7N9 subtype avian influenza virus, inactivated marked vaccine, and its preparation method. This patent describes a recombinant H7N9 subtype avian influenza virus that utilizes a strain JD/17 as the parent virus. The invention involves replacing a peptide sequence in the HA protein of the strain JD/17 with a peptide sequence from the HA protein of H3 subtype. The strain JD/17 has a preservation number of CCTCC No. V201862. The results indicate that the rescued virus maintains similar biological characteristics to the parent virus, such as high HA titers and EID50. Chickens immunized with the marked inactivated and emulsified vaccine produce a high level of antibody, which can be distinguished from antibodies produced by chickens naturally infected with the H7N9 subtype avian influenza virus.

Career Highlights

Xiufan Liu is affiliated with Yangzhou University, where he conducts research and development in the field of infectious diseases. His work has garnered attention for its potential to improve vaccine efficacy and safety.

Collaborations

Xiufan Liu collaborates with notable colleagues, including Daxin Peng and Sujuan Chen. Their combined expertise enhances the research efforts at Yangzhou University and contributes to advancements in vaccine technology.

Conclusion

Xiufan Liu's innovative work in the development of avian influenza vaccines showcases his commitment to improving animal health and public safety. His contributions are vital in the ongoing fight against infectious diseases.